SteadyMed and PHA Aim to Inspire Pulmonary Hypertension Patients with PHenomenal Campaign

SteadyMed and PHA Aim to Inspire Pulmonary Hypertension Patients with PHenomenal Campaign

SteadyMed and the Pulmonary Hypertension Association (PHA) recently launched the PHenomenal campaign, an initiative to offer people with pulmonary hypertension (PH) and their families a platform to share photos and videos of themselves, showing what makes them unique and inspiring.

“My patients with PH continually impress me with their strength, humor and optimism. PH can be a devastating disease, but they refuse to let it define them,” Dr. Fernando Torres, professor of internal medicine at UT Southwestern Medical Center, medical director of the Lung Transplant Program, head of the Pulmonary Hypertension Program, and SteadyMed’s consultant, said in a press release.

The PHenomenal campaign (#PHenomSelf) allows people to tag videos or photos on their social media platforms – like Tumblr, Instagram, Facebook, Youtube or Twitter – and also aims to provide information about the disease.

The two organizations launched  the campaign because, as explained on an Instagram post, “people with PH are not defined by their disease – they are so much more. They are unique, interesting, strong, beautiful, and empowered. In a word, they are PHenomenal.”

“I have been involved with the PH community for more than 22 years, since my daughter Meaghan was first diagnosed,” said Carl Hicks, PHA’s executive vice president. “Since then, I’ve had the privilege to meet many others who continue to amaze and inspire me. I remember Meaghan, who we lost in 2009, as vibrant, joyful and strong, and I am delighted that we are giving others the opportunity to show what makes them unique as well.”

SteadyMed is a specialty pharma company that develops drug products to treat orphan diseases with unmet needs. The company’s lead product candidate is Trevyent, a drug that combines the pharmaceutical’s proprietary PatchPump technology with treprostinil – a vasodilatory prostacyclin analogue – indicated for the treatment of pulmonary arterial hypertension (PAH). Trevyent is a development-stage product that has not yet been approved for sale by the U.S. FDA.

“SteadyMed is committed to honoring the amazing and resilient people who comprise the PH community, and we couldn’t be prouder to be partnering with the PHA to give those with PH and their loved ones an opportunity to share their incredibly inspiring stories,” said Marylyn Rigby, SteadyMed’s senior director of Investor Relations and Marketing.

Leave a Comment